FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078794107> ?p ?o ?g. }

• W2078794107 endingPage "18640" @default.
• W2078794107 startingPage "18633" @default.
• W2078794107 abstract "Sphingosine kinase 1 (SK1) catalyzes the conversion of sphingosine to the bioactive lipid sphingosine 1-phosphate. We have previously demonstrated that FTY720 and (S)-FTY720 vinylphosphonate are novel inhibitors of SK1 activity. Here, we show that (S)-FTY720 vinylphosphonate binds to a putative allosteric site in SK1 contingent on formation of the enzyme-sphingosine complex. We report that SK1 is an oligomeric protein (minimally a dimer) containing noncooperative catalytic sites and that the allosteric site exerts an autoinhibition of the catalytic site. A model is proposed in which (S)-FTY720 vinylphosphonate binding to and stabilization of the allosteric site might enhance the autoinhibitory effect on SK1 activity. Further evidence for the existence of allosteric site(s) in SK1 was demonstrated by data showing that two new FTY720 analogues (a conjugate of sphingosine with a fluorophore and (S)-FTY720 regioisomer) increased SK1 activity, suggesting relief of autoinhibition of SK1 activity. Comparisons with the SK1 inhibitor, SKi or siRNA knockdown of SK1 indicated that (S)-FTY720 vinylphosphonate and FTY720 behave as typical SK1 inhibitors in preventing sphingosine 1-phosphate-stimulated rearrangement of actin in MCF-7 cells. These findings are discussed in relation to the anticancer properties of SK1 inhibitors. Sphingosine kinase 1 (SK1) catalyzes the conversion of sphingosine to the bioactive lipid sphingosine 1-phosphate. We have previously demonstrated that FTY720 and (S)-FTY720 vinylphosphonate are novel inhibitors of SK1 activity. Here, we show that (S)-FTY720 vinylphosphonate binds to a putative allosteric site in SK1 contingent on formation of the enzyme-sphingosine complex. We report that SK1 is an oligomeric protein (minimally a dimer) containing noncooperative catalytic sites and that the allosteric site exerts an autoinhibition of the catalytic site. A model is proposed in which (S)-FTY720 vinylphosphonate binding to and stabilization of the allosteric site might enhance the autoinhibitory effect on SK1 activity. Further evidence for the existence of allosteric site(s) in SK1 was demonstrated by data showing that two new FTY720 analogues (a conjugate of sphingosine with a fluorophore and (S)-FTY720 regioisomer) increased SK1 activity, suggesting relief of autoinhibition of SK1 activity. Comparisons with the SK1 inhibitor, SKi or siRNA knockdown of SK1 indicated that (S)-FTY720 vinylphosphonate and FTY720 behave as typical SK1 inhibitors in preventing sphingosine 1-phosphate-stimulated rearrangement of actin in MCF-7 cells. These findings are discussed in relation to the anticancer properties of SK1 inhibitors. Sphingosine 1-phosphate (S1P) 2The abbreviations used are: S1P, sphingosine 1-phosphate; Bdp-So, Bodipy sphingosine; HER2, human epidermal growth factor receptor-2; Kic, competitive inhibition constant; Kiu, uncompetitive inhibition constant; SK1, sphingosine kinase 1; SKi, 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole. is a bioactive lipid that binds to specific G protein-coupled receptors (S1P1–5). There is a wealth of evidence to demonstrate that S1P plays key roles in regulating many critical processes in cell biology and, indeed, in pathophysiological diseases such as cancer (1Pyne N.J. Pyne S. Nat. Rev. Cancer. 2010; 10: 489-503Crossref PubMed Scopus (675) Google Scholar). The levels of S1P are defined by its synthesis (involving sphingosine kinase, which phosphorylates sphingosine; there are two isoforms termed SK1 and SK2) and removal (involving hydrolysis of S1P catalyzed by S1P lyase or dephosphorylation by S1P phosphatase). To date, emphasis has been placed on the discovery of new molecules that are capable of agonizing/antagonizing S1P1–5. In this regard, FTY720 (FingolimodTM) has been developed as a functional S1P1 antagonist by virtue of its ability to down-regulate S1P1 in T lymphocytes (2Brinkmann V. Davis M.D. Heise C.E. Albert R. Cottens S. Hof R. Bruns C. Prieschl E. Baumruker T. Hiestand P. Foster C.A. Zollinger M. Lynch K.R. J. Biol. Chem. 2002; 277: 21453-21457Abstract Full Text Full Text PDF PubMed Scopus (1314) Google Scholar) and is now licensed (as Gilenya) for oral treatment of multiple sclerosis (3Brinkmann V. Billich A. Baumruker T. Heining P. Schmouder R. Francis G. Aradhye S. Burtin P. Nat. Rev. Drug Discov. 2010; 9: 883-897Crossref PubMed Scopus (963) Google Scholar). FTY720 is a synthetic sphingosine analogue that is taken up by cells and phosphorylated to FTY720 phosphate by SK2 (4Sanchez T. Estrada-Hernandez T. Paik J.H. Wu M.T. Venkataraman K. Brinkmann V. Claffey K. Hla T. J. Biol. Chem. 2003; 278: 47281-47290Abstract Full Text Full Text PDF PubMed Scopus (349) Google Scholar). On release from cells, (S)-FTY720 phosphate binds to four of the five S1P receptors (S1P2 being the exception) (2Brinkmann V. Davis M.D. Heise C.E. Albert R. Cottens S. Hof R. Bruns C. Prieschl E. Baumruker T. Hiestand P. Foster C.A. Zollinger M. Lynch K.R. J. Biol. Chem. 2002; 277: 21453-21457Abstract Full Text Full Text PDF PubMed Scopus (1314) Google Scholar), to elicit polyubiquitination, endocytosis, and degradation of S1P1 in T lymphocytes (5Gräler M.H. Goetzl E.J. FASEB J. 2004; 18: 551-553Crossref PubMed Scopus (461) Google Scholar). S1P/S1P1 is essential for effective T lymphocyte egress and, therefore, the FTY720 phosphate-induced down-regulation of S1P1 on T lymphocytes results in their retention in the lymph (6Mandala S. Hajdu R. Bergstrom J. Quackenbush E. Xie J. Milligan J. Thornton R. Shei G.J. Card D. Koehane C. Rosenbach M. Hale J. Lynch C.L. Rupprecht K. Parsons W. Rosen H. Science. 2002; 296: 346-349Crossref PubMed Scopus (1434) Google Scholar). An alternative therapeutic approach is to use a S1P-neutralizing antibody that reduces bioavailability of S1P at its receptors. This has proven very successful as an antitumorigenic and antiangiogenic agent in a number of disease models (7Visentin B. Vekich J.A. Sibbald B.J. Cavalli A.L. Moreno K.M. Matteo R.G. Garland W.A. Lu Y. Yu S. Hall H.S. Kundra V. Mills G.B. Sabbadini R.A. Cancer Cell. 2006; 9: 225-238Abstract Full Text Full Text PDF PubMed Scopus (413) Google Scholar) and is being tested in clinical trials for cancer and age-related macular degeneration. Thus, current target intervention is confined to inhibiting S1P binding to receptors or limiting bioavailability of S1P at these receptors. Recently, novel intracellular targets of S1P have been identified. Prominent examples are histone deacetylase (8Hait N.C. Allegood J. Maceyka M. Strub G.M. Harikumar K.B. Singh S.K. Luo C. Marmorstein R. Kordula T. Milstien S. Spiegel S. Science. 2009; 325: 1254-1257Crossref PubMed Scopus (748) Google Scholar) and TNF receptor-associated factor-2 (9Alvarez S.E. Harikumar K.B. Hait N.C. Allegood J. Strub G.M. Kim E.Y. Maceyka M. Jiang H. Luo C. Kordulla T. Milstein S. Spiegel S. Nature. 2010; 465: 1084-1088Crossref PubMed Scopus (592) Google Scholar). These findings underscore the importance of limiting the intracellular action of S1P. Indeed, there is evidence for a role for SK1 in human cancers, such as increased levels of SK1 mRNA transcript and/or SK1 protein in cancers of the stomach, lung, brain, colon, kidney, non-Hodgkins lymphoma, and breast (see review, see Ref. 1Pyne N.J. Pyne S. Nat. Rev. Cancer. 2010; 10: 489-503Crossref PubMed Scopus (675) Google Scholar). For example, high expression of SK1 and cognate S1P1 and S1P3 receptors is correlated with poor survival rates and induction of Tamoxifen resistance in estrogen receptor-positive breast cancer patients, where the average survival time is reduced from 18 years to 7.5 years and recurrence of the disease in patients receiving Tamoxifen is shortened by 8 years in the high SK1 expression group (10Long J.S. Edwards J. Watson C. Tovey S. Mair K. Schiff R. Natarajan V. Pyne N.J. Pyne S. Mol. Cell. Biol. 2010; 30: 3827-3841Crossref PubMed Scopus (87) Google Scholar, 11Watson C. Long J.S. Orange C. Tannahill C.L. Mallon E. McGlynn L.M. Pyne S. Pyne N.J. Edwards J. Am. J. Pathol. 2010; 177: 2205-2215Abstract Full Text Full Text PDF PubMed Scopus (140) Google Scholar). In addition, SK1 induces chemotherapeutic resistance in androgen-independent prostate cancer cells (a model for castrate-independent prostate cancer), indicating that this enzyme might have a role in the generic development of chemotherapeutic resistance in cancer (12Loveridge C. Tonelli F. Leclecq T. Lim K.G. Long. S. Berdyshev E. Tate R.J. Natarajan V. Pitson Pyne N.J. Pyne S. J. Biol. Chem. 2010; 285: 38841-38852Abstract Full Text Full Text PDF PubMed Scopus (101) Google Scholar). Moreover, siRNA knockdown of SK1 significantly inhibited aberrant crypt formation and cancer development in a mouse model of colon cancer, suggesting a key role for SK1 in both early and late stages of carcinogenesis (13Kawamori T. Osta W. Johnson K.R. Pettus B.J. Bielawski J. Tanaka T. Wargovich M.J. Reddy B.S. Hannun Y.A. Obeid L.M. Zhou D. FASEB J. 2006; 20: 386-388Crossref PubMed Scopus (191) Google Scholar). Previously, we reported that FTY720 inhibits purified SK1 activity and induces the proteasomal degradation of SK1 in mammalian cells (14Tonelli F. Lim K.G. Loveridge C. Long J. Pitson S.M. Tigyi G. Bittman R. Pyne S. Pyne N.J. Cell. Signal. 2010; 22: 1536-1542Crossref PubMed Scopus (158) Google Scholar). We also established that the (R) and (S) enantiomers of FTY720 vinylphosphonate (S > R) are inhibitors of purified SK1 and demonstrated that (S)-FTY720 vinylphosphonate induced its proteasomal degradation in cells, whereas their saturated counterpart, (R)- or (S)-FTY720 phosphonate, and (S)-FTY720 phosphate do not significantly inhibit the enzyme (14Tonelli F. Lim K.G. Loveridge C. Long J. Pitson S.M. Tigyi G. Bittman R. Pyne S. Pyne N.J. Cell. Signal. 2010; 22: 1536-1542Crossref PubMed Scopus (158) Google Scholar). To elucidate the mechanisms by which specific FTY720 analogues function as SK1 inhibitors, we have now studied their behavior with respect to enzyme inhibition kinetics, proteasomal degradation of SK1, and rearrangement of actin in MCF-7 breast cancer cells. These studies revealed that (S)-FTY720 vinylphosphonate appears to inhibit SK1 via a putative allosteric site interaction. FTY720 and (S)-FTY720 vinylphosphonate induced the proteasomal degradation of SK1 and abrogated the S1P-stimulated rearrangement of actin into lamellipodia/membrane ruffles required for cell migration. These findings indicate that FTY720 analogues are SK1 inhibitors that exhibit novel properties that are favorable for anticancer activity. All general biochemicals and anti-actin antibody were from Sigma. High glucose Dulbecco's modified Eagle's medium (DMEM), Minimum Essential Medium (MEM), penicillin-streptomycin (10,000 units/ml penicillin and 10,000 μg/ml streptomycin) and Lipofectamine 2000TM were from Invitrogen. MCF-7 Neo and MCF-7 HER218 cells were gifts from R. Schiff (Baylor College of Medicine, Houston, TX). Anti-ERK2 antibody was from BD Transduction Laboratories (Oxford, UK), and anti-SK1 antibody was a gift from A. Huwiler (University of Bern, Switzerland). Anti-FLAG M2 antibody was from Stratagene. Anti-myc antibody was from Santa Cruz Biotechnology (Santa Cruz, CA). Sphingosine and S1P were from Avanti Polar Lipids (Alabaster, AL). MG132 and purified SK1 were from Enzo Life Sciences (Exeter, UK). SKi (2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole) was from Merck. FTY720 was from Cayman Chemicals (Tallinn, Estonia). 4′,6-Diamidino-2-phenylindole (DAPI) was from Vector Laboratories. The G113A SK1 mutant was a kind gift from S. Pitson (SA Pathology, Adelaide, Australia). MCF-7 Neo and HER218 breast cancer cells were grown in a monolayer culture in high glucose DMEM with 10% European FCS and 100 units/ml penicillin, 100 μg/ml streptomycin, 0.4% Geneticin (absent for parental cells), and 15 μg/ml insulin at 37 °C with 5% CO2. HEK 293 cells were cultured in MEM supplemented with 10% European FCS, 100 units/ml penicillin, 100 μg/ml streptomycin, and 1% nonessential amino acids at 37 °C in 5% CO2 and in the presence of DMEM (instead of MEM) and 0.8% Geneticin for HEK 293 cells stably overexpressing GFP-tagged SK1. HEK 293 cells were transfected with Lipofectamine 2000TM reagent and myc- or FLAG-tagged SK1 or G113A SK1 plasmid constructs and grown for 48 h. Cells were harvested in sample buffer (125 mm Tris, pH 6.7, 0.5 mm Na4P2O7, 1.25 mm EDTA, 0.5% w/v SDS containing 1.25% v/v glycerol, 0.06% w/v bromphenol blue, and 50 mm dithiothreitol) and were subjected to SDS-PAGE and Western blotting as described previously (15Alderton F. Rakhit S. Kong K.C. Palmer T. Sambi S. Pyne S. Pyne N.J. J. Biol. Chem. 2001; 276: 28578-28585Abstract Full Text Full Text PDF PubMed Scopus (145) Google Scholar). Resolved proteins were Western blotted with anti-myc, anti-FLAG, anti-SK1, anti-ERK2, or anti-actin antibodies. Forty-eight hours after transfection with the indicated plasmid constructs, the medium was removed, and HEK 293 cells were lysed in ice-cold immunoprecipitation buffer (500 μl) containing 20 mm Tris, 137 mm NaCl, 2.7 mm KCl, 1 mm MgCl2, 1 mm CaCl2, 1% (v/v) Nonidet P-40, 10% (v/v) glycerol, 1 mg/ml bovine serum albumin (BSA), 0.5 mm Na4P2O7, 0.2 mm phenylmethanesulfonyl fluoride (PMSF), leupeptin, and aprotinin (all protease inhibitors were at 10 μg/ml, pH 8.0) for 20 min at 4 °C. The material was harvested and transferred to microcentrifuge tubes, which were further mixed for 60 min at 4 °C, and then centrifuged at 14,000 × g for 10 min at 4 °C to remove cellular debris. After preclearing with protein G-Sepharose beads, equal amounts of supernatant from each sample were taken for immunoprecipitation with protein G-Sepharose beads and anti-myc or anti-FLAG antibodies. After 2 h or overnight agitation at 4 °C, the supernatant was removed by centrifugation at 14,000 × g for 15 s at 4 °C. Immunoprecipitates were washed twice with 1 ml of buffer A containing 10 mm HEPES, pH 7.0, 100 mm NaCl, and 0.5% (v/v) Nonidet P-40 and once in 1 ml of buffer A without Nonidet P-40. Immunoprecipitates were collected by centrifugation at 14,000 × g for 15 s at 4 °C and combined with boiling sample buffer for SDS-PAGE. SK1 activity was assayed as described previously (16Delon C. Manifava M. Wood E. Thompson D. Krugmann S. Pyne S. Ktistakis N.T. J. Biol. Chem. 2004; 279: 44763-44774Abstract Full Text Full Text PDF PubMed Scopus (175) Google Scholar). Briefly, sphingosine was solubilized in Triton X-100 (final concentration 0.063% w/v) and combined with buffer 1 containing 20 mm Tris, pH 7.4, 1 mm EDTA, 1 mm Na3VO4, 40 mm β-glycerophosphate, 1 mm NaF, 0.007% (v/v) β-mercaptoethanol, 20% (v/v) glycerol, 10 μg/ml aprotinin, 10 μg/ml soybean trypsin inhibitor, 1 mm PMSF, and 0.5 mm 4-deoxypyridoxine. Modulation of SK1 activity was determined by incubating 15 ng of purified SK1 or 15 μg of HEK 293 cell lysates containing stably overexpressed or transiently expressed recombinant SK1 for 15–20 min at 30 °C, in the presence of 0.5–20 μm sphingosine, 250 μm [γ-32P]ATP (4.4 × 104 cpm/nmol, in 10 mm MgCl2), and varying concentrations of inhibitors dissolved in dimethyl sulfoxide or control (5% dimethyl sulfoxide). Reactions were terminated by the addition of 500 μ1 of n-butyl alcohol and mixed with 1 ml of 2 m KCl. The organic phase containing [32P]S1P was then extracted by washing twice with 1 ml of 2 m KCl before quantification by Cerenkov counting. The kinetic parameters were calculated using the graph plotting and curve fitting programs Biograph (University of Strathclyde, Glasgow, UK) and Prism 4.03 (GraphPad). Substrate kinetics were analyzed according to the Michaelis-Menten equation, and the inhibition constants (Kicand Kiu) were determined using Dixon and Cornish-Bowden plots (17Cortés A. Cascante M. Cárdenas M.L. Cornish-Bowden A. Biochem. J. 2001; 357: 263-268Crossref PubMed Scopus (144) Google Scholar). Cells were plated onto autoclaved 13-mm glass coverslips and grown to 60% confluence before serum starvation for 48 h prior to stimulation. Cells were fixed with 3.7% formaldehyde in PBS for 10 min and permeabilized with 0.1% Triton X-100 in PBS for 1 min before incubation in blocking solution (5% European FCS and 1% BSA in PBS) for 1 h at room temperature. Coverslips were then incubated with phalloidin red (1:100 dilution in blocking solution) for 1 h at room temperature. Coverslips were washed with PBS and mounted on glass slides using Vectashield® hard set mounting medium with DAPI. Actin rearrangement was assessed using phalloidin red staining. Fluorescence was visualized using a Nikon (Surrey, UK) E600 epifluorescence microscope. Densitometric quantification of Western blots was performed using ScanImage program (Scion Corporation, Frederick, MD). Statistical analysis was performed using an unpaired Student's t test. The structural formulas of the FTY720 analogues are shown in Fig. 1, and the synthetic schemes employed to prepare (S)-FTY720 regioisomer and Bodipy-sphingosine (Bdp-So) are outlined in supplemental Fig. 1 and supplemental Experimental Procedures. We have previously demonstrated that SKi (which was identified by French et al.) (18French K.J. Schrecengost R.S. Lee B.D. Zhuang Y. Smith S.N. Eberly J.L. Yun J.K. Smith C.D. Cancer Res. 2003; 63: 5962-5969PubMed Google Scholar), FTY720, and (S)-and (R)-FTY720 vinylphosphonate inhibited purified SK1 activity, whereas (S)- and (R)-FTY720 phosphonate are inactive (12Loveridge C. Tonelli F. Leclecq T. Lim K.G. Long. S. Berdyshev E. Tate R.J. Natarajan V. Pitson Pyne N.J. Pyne S. J. Biol. Chem. 2010; 285: 38841-38852Abstract Full Text Full Text PDF PubMed Scopus (101) Google Scholar, 14Tonelli F. Lim K.G. Loveridge C. Long J. Pitson S.M. Tigyi G. Bittman R. Pyne S. Pyne N.J. Cell. Signal. 2010; 22: 1536-1542Crossref PubMed Scopus (158) Google Scholar). Using HEK 293 cells stably overexpressing SK1 (30-fold increase in SK1 activity versus stable vector-transfected cells), we have now investigated the kinetic mechanism by which SKi, FTY720, and (S)-FTY720 vinylphosphonate inhibit SK1 activity (Table 1). We found that FTY720 is a competitive inhibitor (with sphingosine) with a Kic = 2 ± 0.5 μm (Table 1, Fig. 2A, and supplemental Fig. 2A). (S)-FTY720 vinylphosphonate is an uncompetitive inhibitor (with sphingosine) with a Kiu = 14.5 ± 4.4 μm (Table 1, Fig. 2B, and supplemental Fig. 2B). This kinetic behavior indicates that (S)-FTY720 vinylphosphonate binds to a putative allosteric site in SK1 contingent on formation of the SK1-sphingosine complex. Indeed, when (S)-FTY720 vinylphosphonate concentration was plotted against inhibition of catalysis at a fixed concentration of sphingosine (10 μm), then a Hill coefficient of 1.9 ± 0.2 and an IC50 = 20 ± 1.1 μm were obtained (Fig. 2C). A Hill coefficient of 2.2 ± 0.3 was obtained at 20 μm sphingosine (data not shown). The percent inhibition of stably overexpressed SK1 in HEK 293 cells by 50 μm (S)-FTY720 vinylphosphonate (using 10 μm sphingosine) showed good agreement with our previous findings using purified SK1 (14Tonelli F. Lim K.G. Loveridge C. Long J. Pitson S.M. Tigyi G. Bittman R. Pyne S. Pyne N.J. Cell. Signal. 2010; 22: 1536-1542Crossref PubMed Scopus (158) Google Scholar), and in each case, inhibition of SK1 activity was ∼80%. Additional evidence that SK1 contains an allosteric site(s) was demonstrated by data showing that micromolar concentrations of Bdp-So (a conjugate of sphingosine with the Bodipy fluorophore) and (S)-FTY720 regioisomer, both of which are also relatively weak substrates of SK1, activated purified SK1 activity (Fig. 2D). Bdp-So stimulated SK1 activity in a concentration-dependent manner at a fixed concentration of sphingosine (10 μm) (Fig. 2D). Indeed, SK1 phosphorylated sphingosine in the presence of Bdp-So with a Hill coefficient of 4.5 ± 2.7 (Fig. 2D). SKi is a mixed inhibitor of SK1 with a Kic = 17 ± 3.5 μm and a Kiu = 48.3 ± 11.5 μm and thus was biased toward competitive inhibition at low micromolar concentrations of SKi (Table 1, Fig. 2E, and supplemental Fig. 2C).TABLE 1Kinetic constantsInhibitorInhibition mechanismInhibition constant(s)μmFTY720CompetitiveKic = 2.0 ± 0.5(S)-FTY720 vinylphosphonateUncompetitiveKiu = 14.5 ± 4.4SKiMixedKic = 17.0 ± 3.5; Kiu = 48.3 ± 11.5 Open table in a new tab The data presented in Fig. 3 demonstrate that SK1 is an oligomeric protein. This conclusion is based on results from experiments in which wild-type myc- and FLAG-tagged SK1 are transiently co-expressed in HEK 293 cells and where myc- and FLAG-tagged SK1 (molecular mass = 42 kDa) were co-immunoprecipitated with anti-FLAG antibody (Fig. 3A). Identical results were obtained using anti-myc antibody (Fig. 3B). The ability of SK1 to form oligomers confirms data previously published by Kihara et al. (19Kihara A. Anada Y. Igarashi Y. J. Biol. Chem. 2006; 281: 4532-4539Abstract Full Text Full Text PDF PubMed Scopus (80) Google Scholar). To test whether (S)-FTY720 vinylphosphonate conforms to a model in which inhibitors can stabilize an allosteric site/domain that exerts an autoinhibitory effect on SK1 activity, we created hybrid SK1 oligomers containing wild-type SK1 and kinase-deficient SK1 mutant monomers. The assumption here is that each monomer of the wild enzyme contains one catalytic site and one allosteric site. Thus, co-expression of WT SK1 with D178N SK1 mutant (mutated in the sphingosine binding site) (20Yokota S. Taniguchi Y. Kihara A. Mitsutake S. Igarashi Y. FEBS Lett. 2004; 578: 106-110Crossref PubMed Scopus (40) Google Scholar) or G81D SK1 mutant (mutated in the ATP binding site) (21Pitson S.M. Moretti P.A. Zebol J.R. Xia P. Gamble J.R. Vadas M.A. D'Andrea R.J. Wattenberg B.W. J. Biol. Chem. 2000; 275: 33945-33950Abstract Full Text Full Text PDF PubMed Scopus (170) Google Scholar) will result in formation of hybrid SK1 oligomers containing more allosteric sites compared with catalytic sites. Therefore, if the allosteric site exerts an autoinhibition, then we expect the catalytically deficient SK1 mutants to reduce catalytic activity of WT SK1 in the oligomer. First, we demonstrated that transiently overexpressed FLAG-tagged D178N SK1 mutant and the myc-tagged G81D SK1 mutants can indeed form oligomers with myc-tagged and FLAG-tagged WT SK1, respectively (Fig. 3, A and B). We also confirmed that the FLAG-tagged D178N SK1 mutant exhibited <10% of the activity of the wild-type enzyme (see Fig. 3C). To address directly whether mutant SK1 inhibits the catalytic activity of WT SK1, we transiently co-expressed WT myc-tagged SK1, whose concentration was fixed, with varying amounts of FLAG-tagged D178N SK1 mutant. Under these conditions, the FLAG-tagged D178N SK1 mutant inhibited WT myc-tagged SK1 activity by ∼50% (Fig. 3C). We also evaluated the nature of the inhibition kinetics with (S)-FTY720 vinylphosphonate or FTY720 in HEK 293 cell lysates containing transiently overexpressed WT FLAG/myc-tagged SK1. In common with stably overexpressed WT SK1, (S)-FTY720 vinylphosphonate was an uncompetitive inhibitor (with sphingosine) with a Kiu = 7 μm, whereas FTY720 was a competitive inhibitor with a Kic = 7 μm (data not shown). Finally, we explored the possibility that Gly113 in SK1 might be part of the putative allosteric site as mutation to alanine in SK1 results in constitutive activation of the lipid kinase (22Pitson S.M. Moretti P.A. Zebol J.R. Vadas M.A. D'Andrea R.J. Wattenberg B.W. FEBS Lett. 2001; 509: 169-173Crossref PubMed Scopus (16) Google Scholar). This is a result of an increase in Vmax, without alteration in substrate binding to the enzyme. Therefore, we tested the sensitivity of the G113A mutant SK1 (transiently overexpressed in HEK 293 cells) to (S)-FTY720 vinylphosphonate and Bdp-So. In this regard, (S)-FTY720 vinylphosphonate inhibited and Bdp-So activated the G113A SK1 mutant to an extent similar to that with WT SK1 (Fig. 3D). Previously, we demonstrated an entirely novel mechanism of functional interaction of SK1 inhibitors with SK1 that offers additional opportunities for drug discovery (12Loveridge C. Tonelli F. Leclecq T. Lim K.G. Long. S. Berdyshev E. Tate R.J. Natarajan V. Pitson Pyne N.J. Pyne S. J. Biol. Chem. 2010; 285: 38841-38852Abstract Full Text Full Text PDF PubMed Scopus (101) Google Scholar, 14Tonelli F. Lim K.G. Loveridge C. Long J. Pitson S.M. Tigyi G. Bittman R. Pyne S. Pyne N.J. Cell. Signal. 2010; 22: 1536-1542Crossref PubMed Scopus (158) Google Scholar). These studies involved polyubiquitination, which directs proteasomal degradation of proteins (12Loveridge C. Tonelli F. Leclecq T. Lim K.G. Long. S. Berdyshev E. Tate R.J. Natarajan V. Pitson Pyne N.J. Pyne S. J. Biol. Chem. 2010; 285: 38841-38852Abstract Full Text Full Text PDF PubMed Scopus (101) Google Scholar), and employed the proteasomal inhibitor, MG132 (12Loveridge C. Tonelli F. Leclecq T. Lim K.G. Long. S. Berdyshev E. Tate R.J. Natarajan V. Pitson Pyne N.J. Pyne S. J. Biol. Chem. 2010; 285: 38841-38852Abstract Full Text Full Text PDF PubMed Scopus (101) Google Scholar). We showed that a number of SK1 inhibitors, including (S)-FTY720 vinylphosphonate, induce MG132-sensitive degradation of SK1 (treatment of cells for 6–48 h), thereby removing SK1 from MCF-7 breast cancer and LNCaP prostate cancer cells (12Loveridge C. Tonelli F. Leclecq T. Lim K.G. Long. S. Berdyshev E. Tate R.J. Natarajan V. Pitson Pyne N.J. Pyne S. J. Biol. Chem. 2010; 285: 38841-38852Abstract Full Text Full Text PDF PubMed Scopus (101) Google Scholar, 14Tonelli F. Lim K.G. Loveridge C. Long J. Pitson S.M. Tigyi G. Bittman R. Pyne S. Pyne N.J. Cell. Signal. 2010; 22: 1536-1542Crossref PubMed Scopus (158) Google Scholar). Indeed SK1 is polyubiquitinated, and SKi enhanced the rate at which polyubiquitinated SK1 is degraded by the proteasome (12Loveridge C. Tonelli F. Leclecq T. Lim K.G. Long. S. Berdyshev E. Tate R.J. Natarajan V. Pitson Pyne N.J. Pyne S. J. Biol. Chem. 2010; 285: 38841-38852Abstract Full Text Full Text PDF PubMed Scopus (101) Google Scholar). Moreover, SKi induces a ubiquitin-proteasomal degradation of SK1 via a ceramide-dependent mechanism in LNCaP cells, a consequence of an initial inhibition of SK1 catalytic activity and perturbation of the ceramide-sphingosine-S1P rheostat (12Loveridge C. Tonelli F. Leclecq T. Lim K.G. Long. S. Berdyshev E. Tate R.J. Natarajan V. Pitson Pyne N.J. Pyne S. J. Biol. Chem. 2010; 285: 38841-38852Abstract Full Text Full Text PDF PubMed Scopus (101) Google Scholar). The creation of an SK1-null cancer cell or one with severely reduced SK1 expression results in the onset of apoptosis, as indicated by increased poly(ADP-ribose) polymerase cleavage (12Loveridge C. Tonelli F. Leclecq T. Lim K.G. Long. S. Berdyshev E. Tate R.J. Natarajan V. Pitson Pyne N.J. Pyne S. J. Biol. Chem. 2010; 285: 38841-38852Abstract Full Text Full Text PDF PubMed Scopus (101) Google Scholar). Therefore, we used MCF-7 Neo (which expresses a vector-encoded neomycin resistance gene) (10Long J.S. Edwards J. Watson C. Tovey S. Mair K. Schiff R. Natarajan V. Pyne N.J. Pyne S. Mol. Cell. Biol. 2010; 30: 3827-3841Crossref PubMed Scopus (87) Google Scholar) to establish the effects of SKi, FTY720, and (S)-FTY720 vinylphosphonate on the proteasomal degradation of SK1; we determined whether this might be influenced by an oncogenic background of HER2. As shown in Fig. 4, treatment of MCF-7 Neo cells with SKi, FTY720 or (S)-FTY720 vinylphosphonate for 24 h induced the degradation of SK1 (molecular mass = 42 kDa). We previously observed a HER2-dependent increase in SK1 expression in the MCF-7 HER2 cells (HER218 cells, stably expressing HER2) (10Long J.S. Edwards J. Watson C. Tovey S. Mair K. Schiff R. Natarajan V. Pyne N.J. Pyne S. Mol. Cell. Biol. 2010; 30: 3827-3841Crossref PubMed Scopus (87) Google Scholar). These cells remain sensitive to SKi, FTY720, or (S)-FTY720 vinylphosphonate. Indeed, all three compounds induced the MG132-sensitive proteasomal degradation of SK1 to an extent similar to that with MCF-7 Neo cells (Fig. 4). We have previously shown that siRNA knockdown of SK1 reduced the S1P-induced formation of a migratory phenotype in MCF-7 Neo cells, as assessed by inhibition of S1P-stimulated actin accumulation into membrane ruffles/lamellipodia and inhibited migration of cells in scratch assays; this is mediated by S1P3 (10Long J.S. Edwards J. Watson C. Tovey S. Mair K. Schiff R. Natarajan V. Pyne N.J. Pyne S. Mol. Cell. Biol. 2010; 30: 3827-3841Crossref PubMed Scopus (87) Google Scholar). Actin is clustered into focal adhesions in MCF-7 Neo cells. Treatment of these cells with S1P stimulates the rearrangement of actin from focal adhesions into membrane ruffles/lamellipodia (10Long J.S. Edwards J. Watson C. Tovey S. Mair K. Schiff R. Natarajan V. Pyne N.J. Pyne S. Mol. Cell. Biol. 2010; 30: 3827-3841Crossref PubMed Scopus (87) Google Scholar) (Fig. 5). Treatment of MCF-7 Neo cells with SKi, (S)-FTY720 vinylphosphonate (Fig. 5A), or FTY720 (Fig. 5B) for 15 min reduced the S1P-stimulated rearrangement of actin into lamellipodia/membrane ruffles and reestablished actin focal adhesions, thereby demonstrating activity that is consistent with these compounds functioning as SK1 inhibitors. We demonstrate here for the first time that (S)-FTY720 vinylphosphonate binds to a putative allosteric site(s) in SK1 contingent on formation of a SK1-sphingosine complex. This conclusion is based on the finding that (S)-FTY720 vinylphosphonate inhibited SK1 activity in an uncompetitive manner with a Kiu = 14.5 ± 4.4 μm. We also demonstrate that SK1 is an oligomer, consistent with a model that is conducive to allosterism. Moreover, SK1 appears to contain an allosteric site(s) that exerts an autoinhibitory effect on the catalytic sites. This conclusion is based on the finding that FLAG-tagged D178N SK1 mutant inhibited the catalytic activity of the WT myc-tagged SK1 in an oliogmeric arrangement. There are three alternative explanations for these findings, all of which can be excluded. First, we tested whether minimal dimerization is required to form two competent catalytic sites in a dimer by domain swapping. If this were the case, then mutagenesis of Asp178 might disable one of the catalytic sites formed between WT SK1 and D178N mutant SK1. The ATP binding site in monomer 1 might form a competent active site with the sphingosine binding site in monomer 2. Equally, the ATP binding site in monomer 2 might form a competent active site with the sphingosine binding site in monomer 1. Therefore, the formation of two competent active sites in a dimeric arrangement predicts that co-expression of the two catalytically deficient mutants to equal levels should reconstitute 50% of the wild-type activity. However, we found that co-expression of each mutant did not result in a catalytically competent oligomer (activity of the oligomer (∼10% of WT SK1) was equivalent with that of the D178N mutant SK1). Therefore, oligomerization is not required for formation of two competent catalytic sites by domain swapping. Second, it is possible that formation of oligomers is required for co-operation between catalytic sites. Thus, formation of WT SK1-D178N SK1 oligomers might disrupt this cooperation and reduce SK1 activity. However, SK1 exhibits simple Michaelis-Menten kinetics, and thus, the catalytic sites function independently of each other in the oligomeric arrangement. Third, oligomerization might enable functionalization of the catalytic sites, and mutagenesis of Asp178 might impair oligomerization. However, the D178N mutant SK1 is still able to form oligomers with WT SK1. Because the concentration of competent WT catalytic sites is maintained constant in the experiment, we can, therefore, attribute inhibition of WT SK1 catalytic activity by the D178N mutant to putative allosteric site(s) that exhibit autoinhibitory activity. The allosteric site(s) might exist in an “on” and “off” state in equilibrium (Fig. 6). Therefore, binding of (S)-FTY720 vinylphosphonate to SK1 conforms to a model in which (S)-FTY720 vinylphosphonate might stabilize the on state (which autoinhibits SK1 activity) of the allosteric site (which is predicted to have a longer lifetime than the unbound allosteric site), thereby increasing the lifetime of the autoinhibitory effect of the site on SK1 activity. It follows that the activators of SK1, e.g. Bdp-So and (S)-FTY720 regioisomer, might stabilize the off state, thereby relieving inhibition of SK1 activity by the allosteric site and resulting in activation of the enzyme (Fig. 6). We also demonstrated a Hill coefficient of 1.9–2.2 for the inhibition of SK1 catalytic activity by (S)-FTY720 vinylphosphonate. Thus, stabilization of the on allosteric site conformation by (S)-FTY720 vinylphosphonate will induce equilibrium transition such that the concentration of the on site conformation will increase by mass action. A Hill coefficient of ∼2 suggests that a dimer is likely to contain at least two allosteric sites that function in a cooperative manner. For Bdp-So, we obtained a Hill coefficient of 4.5, suggesting that binding of Bdp-So to the allosteric sites is also cooperative. The mutation of Gly113 to alanine in SK1 results in constitutive activation of the lipid kinase (22Pitson S.M. Moretti P.A. Zebol J.R. Vadas M.A. D'Andrea R.J. Wattenberg B.W. FEBS Lett. 2001; 509: 169-173Crossref PubMed Scopus (16) Google Scholar), suggesting that Gly113 might be part of the allosteric site and that the mutation disables its function. Indeed, one can predict that mutation might trap the allosteric site in the off state, thereby converting SK1 into a form that is resistant to inhibition by (S)-FTY720 vinylphosphonate and activation by Bdp-So. However, the G113A mutant was still sensitive to inhibition by (S)-FTY720 vinylphosphonate and activation by Bdp-So. Therefore, Gly113 is unlikely to be involved in allosterism. We also report that the inhibition of SK1 by SKi conforms to a mixed inhibition model with a Kic = 17 ± 3.5 μm and a Kiu = 48.3 ± 11.5 μm. Therefore, SKi appears to bind to both the catalytic site and the putative allosteric site. The latter is consistent with the observation made by others that inhibition of SK1 activity by SKi is not competitive with the second substrate, ATP (18French K.J. Schrecengost R.S. Lee B.D. Zhuang Y. Smith S.N. Eberly J.L. Yun J.K. Smith C.D. Cancer Res. 2003; 63: 5962-5969PubMed Google Scholar). These authors demonstrated that SKi is relatively specific for SK, with no activity against ERK-2, PI3K, or PKCα (18French K.J. Schrecengost R.S. Lee B.D. Zhuang Y. Smith S.N. Eberly J.L. Yun J.K. Smith C.D. Cancer Res. 2003; 63: 5962-5969PubMed Google Scholar, 23French K.J. Upson J.J. Keller S.N. Zhuang Y. Yun J.K. Smith C.D. J. Pharm. Exp. Ther. 2006; 318: 596-603Crossref PubMed Scopus (219) Google Scholar) and that SKi inhibits proliferation and induces apoptosis of various tumor cell lines (18French K.J. Schrecengost R.S. Lee B.D. Zhuang Y. Smith S.N. Eberly J.L. Yun J.K. Smith C.D. Cancer Res. 2003; 63: 5962-5969PubMed Google Scholar). Indeed, our findings confirm that SKi induces the onset of apoptosis of MCF-7 Neo cells (12Loveridge C. Tonelli F. Leclecq T. Lim K.G. Long. S. Berdyshev E. Tate R.J. Natarajan V. Pitson Pyne N.J. Pyne S. J. Biol. Chem. 2010; 285: 38841-38852Abstract Full Text Full Text PDF PubMed Scopus (101) Google Scholar). A role for SK1 in regulating the survival of MCF-7 breast cancer cells was also evident by studies of Taha et al. (24Taha T.A. Kitatani K. El-Alwani M. Bielawski J. Hannun Y.A. Obeid L.M. FASEB J. 2006; 20: 482-484Crossref PubMed Scopus (128) Google Scholar), who demonstrated that siRNA knockdown of SK1 in MCF-7 breast cancer cells induced apoptosis. This involves caspase activation and is associated with increased ceramide formation and Bax oligomerization. Treatment of MCF-7 Neo and MCF-7 HER218 cells with SKi, FTY720, or (S)-FTY720 vinylphosphonate induced the proteasomal degradation of SK1. The ability of SK1 inhibitors to induce proteasomal degradation of SK1 and to exhibit high efficacy killing of cancer cells is likely dependent on the specific adopted inhibitor-SK1 conformation. This conformation might result in different extents of unfolding of SK1 required for polyubiquitination and proteasomal degradation. This proteasomal degradation is also stimulated in a ceramide-dependent manner due to acute inhibition of SK1 catalytic activity by the inhibitor as we demonstrated previously (12Loveridge C. Tonelli F. Leclecq T. Lim K.G. Long. S. Berdyshev E. Tate R.J. Natarajan V. Pitson Pyne N.J. Pyne S. J. Biol. Chem. 2010; 285: 38841-38852Abstract Full Text Full Text PDF PubMed Scopus (101) Google Scholar). SKi is an effective anticancer agent in vivo and inhibits tumor growth (syngenic tumor model with mammary adenocarcinoma cells) and inflammation (ulcerative colitis model) (23French K.J. Upson J.J. Keller S.N. Zhuang Y. Yun J.K. Smith C.D. J. Pharm. Exp. Ther. 2006; 318: 596-603Crossref PubMed Scopus (219) Google Scholar, 25Maines L.W. Fitzpatrick L.R. French K.J. Zhuang Y. Xia Z. Keller S.N. Upson J.J. Smith C.D. Dig. Dis. Sci. 2008; 53: 997-1012Crossref PubMed Scopus (150) Google Scholar). In addition, FTY720 inhibits the growth of various tumor mouse models (bladder, kidney, prostate, breast, liver, etc.) (26Ubai T. Azuma H. Kotake Y. Inamoto T. Takahara K. Ito Y. Kiyama S. Sakamoto T. Horie S. Muto S. Takahara S. Otsuki Y. Katsuoka Y. Anticancer Res. 2007; 27: 75-88PubMed Google Scholar, 27Azuma H. Takahara S. Horie S. Muto S. Otsuki Y. Katsuoka Y. J. Urol. 2003; 169: 2372-2377Crossref PubMed Scopus (103) Google Scholar, 28Chua C.W. Lee D.T. Ling M.T. Zhou C. Man K. Ho J. Chan F.L. Wang X. Wong Y.C. Int. J. Cancer. 2005; 117: 1039-1048Crossref PubMed Scopus (74) Google Scholar, 29Azuma H. Takahara S. Ichimaru N. Wang J.D. Itoh Y. Otsuki Y. Morimoto J. Fukui R. Hoshiga M. Ishihara T. Nonomura N. Suzuki S. Okuyama A. Katsuoka Y. Cancer Res. 2002; 62: 1410-1419PubMed Google Scholar) and also reduces tumor vascularization and angiogenesis (30Ho J.W. Man K. Sun C.K. Lee T.K. Poon R.T. Fan S.T. Mol. Cancer Ther. 2005; 4: 1430-1438Crossref PubMed Scopus (81) Google Scholar). In light of our current findings, it remains to be determined whether the in vivo efficacy in cancer models of SKi and FTY720 is related to the ability of these compounds to inhibit SK1 catalytic activity and/or to induce proteasomal degradation of SK1. In conclusion, the removal of SK1 from cancer cells by SK1 inhibitors suggests that the efficacy and duration of action of these compounds in inducing apoptosis might be significantly superior compared with compounds that simply reversibly inhibit enzyme catalytic activity and are therefore short acting. Moreover, the presence of a putative allosteric site(s) in SK1 offers opportunities for the implementation of new drug discovery programs. Taken together, these findings provide impetus for developing SK1 inhibitors, e.g. by using (S)-FTY720 vinylphosphonate as the prototype, as putative anticancer agents, not least because their mechanism of action should enable fewer administrations to the patient and development of resistance might be impaired, thereby opening new avenues for combination therapies. Download .pdf (.1 MB) Help with pdf files" @default.
• W2078794107 created "2016-06-24" @default.
• W2078794107 creator A5004191810 @default.
• W2078794107 creator A5004530946 @default.
• W2078794107 creator A5019259988 @default.
• W2078794107 creator A5023834954 @default.
• W2078794107 creator A5029388712 @default.
• W2078794107 creator A5060561968 @default.
• W2078794107 creator A5089452476 @default.
• W2078794107 date "2011-05-01" @default.
• W2078794107 modified "2023-09-30" @default.
• W2078794107 title "FTY720 Analogues as Sphingosine Kinase 1 Inhibitors" @default.
• W2078794107 cites W1976339357 @default.
• W2078794107 cites W1978831789 @default.
• W2078794107 cites W1982920137 @default.
• W2078794107 cites W1983079076 @default.
• W2078794107 cites W1983092575 @default.
• W2078794107 cites W1984179269 @default.
• W2078794107 cites W1995093204 @default.
• W2078794107 cites W1996605319 @default.
• W2078794107 cites W1997458456 @default.
• W2078794107 cites W2004527355 @default.
• W2078794107 cites W2020730385 @default.
• W2078794107 cites W2023293937 @default.
• W2078794107 cites W2024106968 @default.
• W2078794107 cites W2043847489 @default.
• W2078794107 cites W2045972295 @default.
• W2078794107 cites W2047607345 @default.
• W2078794107 cites W2051917023 @default.
• W2078794107 cites W2055636600 @default.
• W2078794107 cites W2079368297 @default.
• W2078794107 cites W2097202436 @default.
• W2078794107 cites W2108813293 @default.
• W2078794107 cites W2113891687 @default.
• W2078794107 cites W2117773251 @default.
• W2078794107 cites W2136584723 @default.
• W2078794107 cites W2154089780 @default.
• W2078794107 cites W2155497355 @default.
• W2078794107 cites W2167876561 @default.
• W2078794107 doi "https://doi.org/10.1074/jbc.m111.220756" @default.
• W2078794107 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3099679" @default.
• W2078794107 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21464128" @default.
• W2078794107 hasPublicationYear "2011" @default.
• W2078794107 type Work @default.
• W2078794107 sameAs 2078794107 @default.
• W2078794107 citedByCount "105" @default.
• W2078794107 countsByYear W20787941072012 @default.
• W2078794107 countsByYear W20787941072013 @default.
• W2078794107 countsByYear W20787941072014 @default.
• W2078794107 countsByYear W20787941072015 @default.
• W2078794107 countsByYear W20787941072016 @default.
• W2078794107 countsByYear W20787941072017 @default.
• W2078794107 countsByYear W20787941072018 @default.
• W2078794107 countsByYear W20787941072019 @default.
• W2078794107 countsByYear W20787941072020 @default.
• W2078794107 countsByYear W20787941072021 @default.
• W2078794107 countsByYear W20787941072022 @default.
• W2078794107 crossrefType "journal-article" @default.
• W2078794107 hasAuthorship W2078794107A5004191810 @default.
• W2078794107 hasAuthorship W2078794107A5004530946 @default.
• W2078794107 hasAuthorship W2078794107A5019259988 @default.
• W2078794107 hasAuthorship W2078794107A5023834954 @default.
• W2078794107 hasAuthorship W2078794107A5029388712 @default.
• W2078794107 hasAuthorship W2078794107A5060561968 @default.
• W2078794107 hasAuthorship W2078794107A5089452476 @default.
• W2078794107 hasBestOaLocation W20787941071 @default.
• W2078794107 hasConcept C166342909 @default.
• W2078794107 hasConcept C170493617 @default.
• W2078794107 hasConcept C181199279 @default.
• W2078794107 hasConcept C185592680 @default.
• W2078794107 hasConcept C2776596873 @default.
• W2078794107 hasConcept C2777550365 @default.
• W2078794107 hasConcept C2777700496 @default.
• W2078794107 hasConcept C2778703144 @default.
• W2078794107 hasConcept C55493867 @default.
• W2078794107 hasConcept C86803240 @default.
• W2078794107 hasConceptScore W2078794107C166342909 @default.
• W2078794107 hasConceptScore W2078794107C170493617 @default.
• W2078794107 hasConceptScore W2078794107C181199279 @default.
• W2078794107 hasConceptScore W2078794107C185592680 @default.
• W2078794107 hasConceptScore W2078794107C2776596873 @default.
• W2078794107 hasConceptScore W2078794107C2777550365 @default.
• W2078794107 hasConceptScore W2078794107C2777700496 @default.
• W2078794107 hasConceptScore W2078794107C2778703144 @default.
• W2078794107 hasConceptScore W2078794107C55493867 @default.
• W2078794107 hasConceptScore W2078794107C86803240 @default.
• W2078794107 hasIssue "21" @default.
• W2078794107 hasLocation W20787941071 @default.
• W2078794107 hasLocation W20787941072 @default.
• W2078794107 hasLocation W20787941073 @default.
• W2078794107 hasLocation W20787941074 @default.
• W2078794107 hasOpenAccess W2078794107 @default.
• W2078794107 hasPrimaryLocation W20787941071 @default.
• W2078794107 hasRelatedWork W1991575691 @default.
• W2078794107 hasRelatedWork W2051565928 @default.
• W2078794107 hasRelatedWork W2078794107 @default.
• W2078794107 hasRelatedWork W2083397512 @default.
• W2078794107 hasRelatedWork W2084654786 @default.

• next